Piribedil in Parkinson's syndrome: A clinical study
- 1 January 1975
- journal article
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 8 (3) , 223-226
- https://doi.org/10.1007/bf00567119
Abstract
The effect of a new dopamine receptor stimulating agent, piribedil (ET 495), was studied in 10 patients with Parkinson's syndrome, who had had no or a poor response to previous L-DOPA treatment, or had displayed marked side effects during L-DOPA administration. Piribedil produced significant improvement of the functions of activity of daily living (ADL), and appeared to have a preferential effect on parkinsonian tremor. However, treatment was difficult to control primarily because of severe psychiatric side effects.Keywords
This publication has 10 references indexed in Scilit:
- Tremor and Involuntary Movements in Monkeys: Effect of L-Dopa and of a Dopamine Receptor Stimulating AgentScience, 1973
- ET495 and brain catecholamine mechanisms: Evidence for stimulation of dopamine receptorsEuropean Journal of Pharmacology, 1972
- Tremor Inhibition in Parkinson Syndrome After Apomorphine Administration Under L-Dopa and Decarboxylase-Inhibitor Basic TherapyPharmacopsychiatry, 1972
- CLINICAL ANALYSES OF FACTORS INFLUENCING L‐DOPA TREATMENT OF PARKINSON'S SYNDROMEActa Medica Scandinavica, 1972
- Evidence for a new type of dopamine receptor stimulating agentJournal of Pharmacy and Pharmacology, 1971
- Similarities between Neurologic Effects of L-Dopa and of ApomorphineNew England Journal of Medicine, 1970
- Cardiovascular effects of the 1-(2″ pyrimidyl)-4 piperonyl piperazine (ET 495)European Journal of Pharmacology, 1969
- Synthesis and vasodilator activity of new piperazine derivativesJournal of Medicinal Chemistry, 1968
- Evidence for dopamine receptor stimulation by apomorphineJournal of Pharmacy and Pharmacology, 1967
- Mode of action of apomorphine and dexamphetamine on gnawing compulsion in ratsPsychopharmacology, 1967